An overview on benzylisoquinoline derivatives with dopaminergic and serotonergic activities

Current Medicinal Chemistry

Volumn 16, Issue 19, 2009, Pages 2441-2467

  Cabedo, N ^a   Berenguer, I ^b   Figadere B ^c   Cortes, D ^b  

^a UNIVERSITAT POLITÈCNICA DE VALÈNCIA   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

^c CNRS   (France)

Author keywords

Benzylisoquinoline derivatives; Dopamine receptors; Molecular modelling; Serotonin receptors; Structure activity relationships

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; APOMORPHINE; APORPHINE DERIVATIVE; BENZYLISOQUINOLINE DERIVATIVE; BENZYLTETRAHYDROISOQUINOLINE; BERBINE DERIVATIVE; CULARINE DERIVATIVE; DOPAMINE RECEPTOR; HEXAHYDROBENZO[A]PHENANTHRIDINE; ISOQUINOLINE DERIVATIVE; NAPTHOISOQUINOLINE DERIVATIVE; PHENANTHRIDINE DERIVATIVE; SEROTONIN RECEPTOR; TETRAHYDROISOQUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; CATECHOLAMINERGIC SYSTEM; CONFORMATIONAL TRANSITION; DOPAMINERGIC ACTIVITY; DOPAMINERGIC SYSTEM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; HALOGENATION; HUMAN; NEUROTRANSMISSION; NONHUMAN; REVIEW; SEROTONINERGIC SYSTEM; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; SUBSTITUTION REACTION;

EID: 70349392377     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986709788682100     Document Type: Review

References (217)

1. 2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases. Neuropsychopharmacology, 1987, 1, 5-15.
2. 1 dopamine receptor mRNA in brain supports a role in cognitive, affective, and neuroendocrine aspects of dopaminergic neurotransmission. Proc. Natl. Acad. Sci. U.S.A., 1991, 88, 3772-3776.
3. Missale, C.; Nash, S.R.; Robinson, S.W.; Jaber, M.; Caron, M.G. Dopamine receptors: From structure to function. Physiol. Rev., 1998, 78, 189-225.
4. Marsden, C.A. Dopamine: The rewarding years. Br. J. Pharmacol., 2006, 147, 136-144.
5. Rashid, A.J.; O'Dowd, B.F.; Verma, V.; George, S.R. Neuronal Gq/ 11-coupled dopamine receptors: An uncharted role for dopamine. Trends Pharmacol. Sci., 2007, 28, 551-555.
6. Kebabian, J.W.; Calne, D.B. Multiple receptors for dopamine. Nature, 1979, 277, 93-96.
7. 2 dopamine receptor cDNA. Nature, 1988, 336, 783-787.
8. 2 dopamine receptor isoforms. Nature, 1989, 342, 923-926.
9. 3) as a target for neuroleptics. Nature, 1990, 347, 146-149.
10. 1 dopamine receptor. Nature, 1990, 347, 72-76.
11. 1 dopamine receptors. Int. Rev. Neurobiol., 2001, 48, 65-139.
12. Civelli, O.; Bunzow, J.R.; Grandy, D.K. Molecular diversity of the dopamine receptors. Annu. Rev. Pharmacol. Toxicol., 1993, 32, 281-307.
13. Neve, K.A.; Seamans, J.K.; Trantham-Davidson, H. Dopamine receptor signalling. J. Recep. Signal Transduct. Res., 2004, 24, 165-205.
14. 3 dopamine receptor: Neurobiology and potential clinical relevance. Pharmacol. Rev., 1997, 49, 231-252.
15. Carlsson, A. Dopamine receptor agonists: Intrinsic activity vs. state of receptor. J. Neural. Transm., 1983, 57, 309-315.
16. Clark, D.; Hjorth, S.; Carlsson, A. Dopamine receptor agonists: mechanisms underlying autoreceptor selectivity. I. Review of the evidence. J. Neural. Transm., 1985, 62, 1-52.
17. Clark, D.; Hjorth, S.; Carlsson, A. Dopamine receptor agonists: mechanisms underlying autoreceptor selectivity. II. Theoretical considerations. J. Neural. Transm., 1985, 62, 171-207.
18. Tamminga, C.A. Partial dopamine agonists and the treatment of psychosis. Curr. Neuropharmacol., 2005, 3, 3-8.
19. Gainetdinov, R.R.; Caron, M.G. Monoamine transporters: From genes to behaviour. Annu. Rev. Pharmacol. Toxicol., 2003, 43, 261-284.
20. Bobb, A.J.; Castellanos, F.X.; Addington, A.M.; Rapoport, J.L. Molecular genetic studies of ADHD: 1991 to 2004. Am. J. Med. Genet. B (Neuropsychiatr. Genet.), 2006, 141, 551-565.
21. Howell, L.L.; Wilcox, K.M. The dopamine transporter and cocaine medication development: Drug self-administration in nonhuman primates. J. Pharmacol. Exp. Ther., 2001, 298, 1-6.
22. Hamon, M. Neuropharmacology of anxiety: Perspectives and prospects. Trends Pharmacol. Sci., 1994, 15, 36-39.
23. Meneses, A.; Hong, E. A pharmacological analysis of serotonergic receptors: Effects of their activation of blockade in learning. Prog. Neuropsychopharmacol. Biol. Psychiatry, 1997, 21, 273-296.
24. Heninger, G.R. Serotonin, sex, and psychiatric illness. Proc. Natl. Acad. Sci. U.S.A., 1997, 94, 4823-4824.
25. Busatto, G.F.; Kerwin, R.W. Perspectives on the role of serotonergic mechanisms in the pharmacology of schizophrenia. J. Psychopharmacol., 1997, 11, 3-12.
26. Walsh, B.-T.; Devlin, M.J. Eating disorders: Progress and problems. Science, 1998, 280, 1387-1390.
27. Meltzer, C.C.; Smith, G.; Dekosky, S.T.; Pollock, B.G.; Mathis, C.A.; Moore, R.Y.; Kupfer, D.J.; Reynolds, C.F. III. Serotonin in aging, late-life depression, and Alzheimer's disease: The emerging role of functional imaging. Neuropsychopharmacology, 1998, 18, 407-430.
28. Goadsby, P.J. Serotonin receptors and the acute attack of migraine. Clin. Neurosci., 1998, 5, 18-23.
29. Maron, E.; Shlik, J. Serotonin function in panic disorder: Important, but why? Neuropharmacology, 2006, 31, 1-11.
30. Hoyer, D.; Clarke, D.E.; Fozard, J.R.; Hartig, P.R.; Martin, G.R.; Mylecharane, E.J.; Saxena, P.R.; Humphrey, P.P. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol. Rev., 1994, 46, 157- 03.
31. Bikker, J.A.; Trumpp-Kallmeyer, S.; Humblet, C. G-protein coupled receptors: Models, mutagenesis, and drug design. J. Med. Chem., 1998, 41, 2911-2927.
32. Raymond, J.R.; Mukhin, Y.V.; Gelasco, A.; Turner, J.; Collinsworth, G.; Gettys, T.W.; Grewal, J.S.; Garnovskaya, M.N. Multiplicity of mechanisms of serotonin receptor signal transduction. Pharmacol. Ther., 2001, 92, 179-212.
33. Hoyer, D.; Hannon, J.P.; Martin, G.R. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol. Biochem. Behav., 2002, 71, 533-554.
34. 7. J. Med. Chem., 2003, 46, 2795-2812.
35. 1 receptor subtypes in the brain of control or 5,7-dihydroxytryptamine-treated rats. J. Neurosci., 1986, 6, 3474-3482.
36. 1D receptor subtypes. Trends Pharmacol. Sci., 1996, 17, 103-105.
37. Barnes, N.M.; Sharp, T. A review of central 5-HT receptors and their function. Neuropharmacology, 1999, 38, 1083-1152
38. 1A receptors. J. Neurochem., 2000, 74, 347-357.
39. 2C receptors. Trends Pharmacol. Sci., 2005, 26, 625-630.
40. 3 receptors: Pharmacologic and therapeutic aspects. J. Clin. Pharmacol., 1995, 35, 845-855
41. 4 receptors. FASEB J., 1996, 10, 1398-1407.
42. 5 receptors. Curr. Drug Targets CNS Neurol. Disord., 2004, 3, 53-58.
43. 6 receptors. Curr. Drug Targets CNS Neurol. Disord., 2004, 3, 59-79.
44. Roberts, C.; Price, G.W. Interaction of serotonin autoreceptor antagonists in the rat dorsal raphe nucleus: An in vitro fast cyclic voltammetry study. Neurosci. Lett., 2001, 300, 45-48.
45. Roberts, C.; Price, G.W.; Middlemiss, D.N. Ligands for the investigation of 5-HT autoreceptor function. Brain Res. Bull., 2001, 56, 463-469.
46. 11C-McN 5652 in healthy humans. J. Nucl. Med., 2004, 45, 682-694.
47. Zhu, C.-B.; Hewlett, W.A.; Feoktistov, I.; Biaggioni, I.; Blakely, R.D. Adenosine receptor, protein kinase G, and p38 mitogen-activated protein kinase-dependent up-regulation of serotonin transporters involves both transporter trafficking and activation. Mol. Pharmacol., 2004, 65, 1462-1474.
48. Plisson, C.; Jarkas, N.; McConathy, J.; Voll, R.J.; Votaw, J.; Williams, L.; Howell, L.L.; Kilts, C.D.; Goodman, M.M. Evaluation of carbon-11-labeled 2β-carbomethoxy-3β-4′-((Z)-2-iodoethenyl) phenylnortropane as a potential radioligand for imaging the serotonin transporter by PET. J. Med. Chem., 2006, 49, 942-946.
49. Bentley, K.W. β-Phenylethylamines and isoquinoline alkaloids. Nat. Prod. Rep., 2000, 17, 247-268.
50. Bentley, K.W. β-Phenylethylamines and isoquinoline alkaloids. Nat. Prod. Rep., 2001, 18, 148-170.
51. Bentley, K.W. β-Phenylethylamines and isoquinoline alkaloids. Nat. Prod. Rep., 2002, 19, 332-356.
52. Bentley, K.W. β-Phenylethylamines and isoquinoline alkaloids. Nat. Prod. Rep., 2003, 20, 342-365.
53. Bentley, K.W. β-Phenylethylamines and isoquinoline alkaloids. Nat. Prod. Rep., 2004, 21, 395-424.
54. Bentley, K.W. β-Phenylethylamines and isoquinoline alkaloids. Nat. Prod. Rep., 2005, 22, 249-268.
55. Bentley, K.W. β-Phenylethylamines and isoquinoline alkaloids. Nat. Prod. Rep., 2006, 23, 444-463.
56. Solmajer, P.; Kocjan, D.; Solmajer, T. Conformational study of catecholamines in solution. Z. Naturforsch., 1983, 38c, 758-762.
57. Urban, J.J.; Cramer, C.J.; Famini, G.R. A computational study of solvent effects on the conformation of dopamine. J. Am. Chem. Soc., 1992, 114, 8226-8231.
58. Nagy, P.I.; Alagona, G.; Ghio, C. Theoretical studies on the conformation of protonated dopamine in the gas phase and in aqueous solution. J. Am. Chem. Soc., 1999, 121, 4804-4815
59. Aliste, M.P.; Cassels, B.K. Computational study on the conformations of dopamine, its α- and ortho methylated derivatives and their N-protonated forms. J. Chem. Soc. Perkin Trans. 2, 2001, 906-915.
60. Nichols, D.E. The development of novel dopamine agonists. In Dopamine Receptors; Kaiser, C., Kebabian, J.W., Eds.; ACS, Symposium Series 224; American Chemical Society: Washington, DC, 1983; pp. 201-218.
61. 1 dopamine receptor agonists: Pharmacophore assessment and receptor mapping. J. Med. Chem., 1996, 39, 285-296.
62. 1 receptor full agonist. J. Med. Chem., 2006, 49, 6848-6857.
63. 1A receptor binding modes of the enantiomers of 5-OMe-BPAT. Bioorg. Med. Chem., 1999, 7, 1805-1820.
64. Claudi, F.; Di Stefano, A.; Napolitani, F.; Cingolani, G.M.; Giorgioni, G.; Fontenla, J.A.; Montenegro, G.Y.; Rivas, M.E.; Rosa, E.; Michelotto, B.; Orlando, G.; Brunetti, L. Binding and preliminary evaluation of 5-hydroxy- and 10-hydroxy-2,3,12,12a-tetrahydro- 1H-1benzoxepino2,3,4-ijisoquinolines as dopamine receptor ligands. J. Med. Chem., 2000, 43, 599-608.
65. 2 dopamine receptor. Trends Neurosci., 1990, 9, 373-378.
66. Hibert, M.F.; Trumpp-Kallmeyer, S.; Bruinvels, A.; Hoflack, J. Three-dimensional models of neurotransmitter G-binding protein-coupled receptors. Mol. Pharmacol., 1991, 40, 8-15.
67. 2-like dopamine receptors. Biochem. J., 1992, 287, 277-282.
68. 1A receptor interactions. J. Med. Chem., 1995, 38, 647-658.
69. 1A dopamine receptors. J. Med. Chem., 1996, 39, 850-859.
70. 3 receptor agonists. J. Med. Chem., 2005, 48, 5771-5779.
71. 1 agonist containing a rigid β-phenyldopamine pharmacophore. J. Med. Chem., 1996, 39, 549-555.
72. 1 full agonist. J. Med. Chem., 1990, 33, 1756-1764
73. Neumeyer, J.L. In The Chemistry and Biology of Isoquinoline Alkaloids; Phillipson, J.D., Roberts M.F., Zenk, M.H., Eds.; Springer-Verlag: Berlin/Heidelberg, 1985; pp. 146-170.
74. Ríos, J.L.; Máñez, S.; Giner, R.M.; Recio, M.C. Biological aspects of aporphinoid alkaloids. In The Alkaloids; Cordell, G.A., Ed.; Academic Press: New York, 2000; Vol. 53, pp. 57-117.
75. Zhang, A.; Zhang, Y.; Branfman, A.R.; Baldessarini, R.J.; Neumeyer, J.L. Advances in development of dopaminergic aporphinoids. J. Med. Chem., 2007, 50, 171-181.
76. Zhang, A.; Neumeyer, J.L.; Baldessarini, R.J. Recent progress in development of dopamine receptor subtype-selective agents: Potential therapeutics for neurological and psychiatric disorders. Chem. Rev., 2007, 107, 274-302.
77. Dépatie, L.; Lal, S. Apomorphine and the dopamine hypothesis of schizophrenia: A dilemma? J. Psychiatry Neurosci., 2001, 26, 203-220.
78. Neumeyer, J.L.; Baldessarini, R.J.; Booth, R.J. In Burger's Medicinal Chemistry and Drug Discovery; Abraham, D.J., Ed.; 6th ed.; Wiley & Sons: New York, 2003; Vol. 6, pp. 711-742.
79. Tyne, H.L.; Parsons, J.; Sinnott, A.; Fox, S.H.; Fletcher, N.A.; Steiger, M.J. A 10 year retrospective audit of long-term apomorphine use in Parkinson's disease. J. Neurol., 2004, 251, 1370-1374.
80. Menon, M.K.; Clark, W.G.; Neumeyer, J.L. Comparison of the dopaminergic effects of apomorphine and (-)-N-n-propylnorapomorphine. Eur. J. Pharmacol., 1978, 52, 1-9.
81. Cassels, B.K.; Asencio, M. Monoaminergic, ion channel and enzyme inhibitory activities of natural aporphines, their analogues and derivatives. Nat. Prod. Commun., 2008, 3, 643-653.
82. Neumeyer, J.L.; Granchelli, F.E. Aporphines.11. Synthesis and dopaminergic activity of monohydroxyaporphines. Total synthesis of (±)-11-hydroxyaporphine, (±)-11-hydroxynoraporphine and (±)- 11-hydroxy-N-n-propylnoraporphine. J. Med. Chem., 1974, 17, 1090-1095.
83. Gao, Y.; Zong, R.; Campbell, A.; Kula, N.S.; Baldessarini, R.J.; Neumeyer, J.L. Synthesis and dopamine agonist and antagonist effects of (R)-(-) and (S)-(+)-11-hydroxy-N-n-propylnoraporphine. J. Med. Chem., 1988, 31, 1392-1396.
84. Neumeyer, J.L.; Arana, G.W.; Law, S.-J.; Lamont, J.S.; Kula, N.S.; Baldessarini, R.J. Aporphines.36. Dopamine receptor interactions of trihydroxyaporphines. Synthesis, radioreceptor binding, and striatal adenylate-cyclase stimulation of 2,10,11-trihydroxyaporphines in comparison with other hydroxylated aporphines. J. Med. Chem., 1981, 24, 1440-1445.
85. Neumeyer, J.L.; Gao, Y.; Kula, N.S.; Baldessarini, R.J. R and S enantiomers of 11-hydroxy-N-allylnoraporphine and 10,11-dihydroxy-N-allylnoraporphine. Synthesis and affinity for dopamine receptors in rat brain tissue. J. Med. Chem., 1991, 34, 24-28.
86. Csutoras, C; Zhang, A.; Zhang, K.; Kula, N.S.; Baldessarini, R.J. Neumeyer, J.L. Synthesis and neuropharmacological evaluation of R-(-)-N-alkyl-11-hydroxynoraporphines and their esters. Bioorg. Med. Chem., 2004, 12, 3553-3559.
87. Schaus, J.M.; Titus, R.D.; Foreman, M.M.; Mason, N.R.; Truex, L.L. Aporphines as antagonists of dopamine D1 receptors. J. Med. Chem., 1990, 33, 600-607.
88. 1A receptor ligands. Bioorg. Med. Chem. Lett., 2007, 17, 4128-4130.
89. Dajas-Bailador, F.A.; Asencio, M.; Bonilla, C.; Scorza, M.C.; Echeverry, C.; Reyes-Parada, M.; Silveira, R.; Protais, P.; Russell, G.; Cassels, B.K.; Dajas, F. Dopaminergic pharmacology and antioxidant properties of pukateine, a natural product lead for the design of agents increasing dopamine neurotransmission. Gen. Pharmacol., 1999, 32, 373-379.
90. 50) of an enzymatic reaction. Biochem. Pharmacol., 1973, 22, 3099-3108.
91. 2, and agonist receptor sites in rat brain. J. Med. Chem., 1990, 33, 39-44.
92. 1A receptor interactions. J. Med. Chem., 1996, 39, 3503-3513.
93. 2 receptor selectivity. J. Med. Chem., 2008, 51, 983-987.
94. Neumeyer, J.L.; Arana, G.W.; Ram, V.J.; Kula, N.S.; Baldessarini, R.J. Aporphines.39. Synthesis, dopamine receptor binding, and pharmacological activity of (R)-(-)- and (S)-(+)-2-hydroxyapomorphine. J. Med. Chem., 1982, 25, 990-992.
95. Ramsby, S.; Neumeyer, J.L.; Grigoriadis, D.; Seeman, P. 2-Haloaporphines as potent dopamine agonists. J. Med. Chem., 1989, 32, 1198-1201.
96. Gao, Y.; Baldessarini, R.J.; Kula, N.S.; Neumeyer, J.L. Synthesis and dopamine receptor affinities of enantiomers of 2-substituted apomorphines and their N-n-propyl analogs. J. Med. Chem., 1990, 33, 1800-1805.
97. 2 agonist. J. Med. Chem., 1990, 33, 3122-3124.
98. 2 agonist. Org. Lett., 2005, 7, 3239-3242.
99. Søndergaard, K.; Kristensen, J.L.; Palner, M.; Gillings, N.; Knudsen, G.M.; Roth, B.L.; Begtrup, M. Synthesis and binding studies of 2-arylapomorphines. Org. Biomol. Chem., 2005, 3, 4077-4081.
100. Tóth, M.; Berényi, S.; Csutorás, C.; Kula, N.S.; Zhang, K.; Baldessarini, R.J.; Neumeyer, J.L. Synthesis and dopamine receptor binding of sulfur-containing aporphines. Bioorg. Med. Chem., 2006, 14, 1918-1923.
101. Si, Y.-G.; Gardner, M.P.; Tarazi, F.I.; Baldessarini, R.J.; Neumeyer, J.L. Synthesis and binding studies of 2-O- and 11-O-substituted N-alkylnoraporphines. Bioorg. Med. Chem. Lett., 2008, 18, 3971-3973.
102. Neumeyer, J.L.; Reischig, D.; Arana, G.W.; Campbell, A.; Baldessarini, R.J.; Kula, N.S.; Watling, K.J. Aporphines.48. Enantioselectivity of ( R)-(-) and (S)-(+)-N-n-propylnorapomorphine on dopamine receptors. J. Med. Chem., 1983, 26, 516-521.
103. Baldessarini, R.J.; Kula, N.S.; Zong, R.; Neumeyer, J.L. Receptor affinities of aporphine enantiomers in rat brain tissue. Eur. J. Pharmacol., 1994, 254, 199-203.
104. Campbell, A.; Baldessarini, R.J.; Teicher, M.H.; Neumeyer, J.L. Behavioral-effects of apomorphine isomers in the rat-selective locomotor-inhibitory effects of S-(+)-N-n-propylnorapomorphine. Psychopharmacology, 1986, 88, 158-164.
105. Froimovitz, M.; Neumeyer, J.L.; Baldessarini, R.J. A stereochemical explanation of the dopamine agonist and antagonist activity of stereoisomeric pairs. J. Med. Chem., 1986, 29, 1570-1573.
106. Campbell, A.; Baldessarini, R.J.; Gao, Y.; Zong, R.; Neumeyer, J.L. ( R)-(-)- and (S)-(+)-stereoisomers of 11-hydroxy- and 11-methoxy-N-n-propylnoraporphine: Central dopaminergic behavioral activity in the rat. Neuropharmacology, 1990, 29, 527-536.
107. Campbell, A.; Yeghiayan, S.; Baldessarini, R.J.; Neumeyer, J.L. Selective antidopaminergic effects of S-(+)-N-n-propylnoraporphines in limbic versus extrapyramidal sites in rat brain: Comparisons with typical and atypical antipsychotic agents. Psychopharmacology, 1991, 103, 323-329.
108. 4-like dopamine receptors. Neuropsychopharmacology, 1997, 17, 186-196.
109. Booth, R.G.; Baldessarini, R.J.; Kula, N.S.; Gao, Y.; Zong, R.; Neumeyer, J.L. Presynaptic inhibition of dopamine synthesis in rat striatal tissue by enantiomeric mono- and dihydroxyaporphines. Mol. Pharmacol., 1990, 38, 92-101.
110. Asencio, M.; Delaquerriere, B.; Cassels, B.K.; Speisky, H.; Comoy, E.; Protais, P. Biochemical and behavioral effects of boldine and glaucine on dopamine systems. Pharmacol. Biochem. Behav., 1999, 62, 7-13.
111. 2 dopaminergic receptors: Halogenation and D1 receptor selectivity. Bioorg. Med. Chem., 2005, 13, 3699-3704.
112. Sobarzo-Sanchez, E.M.; Arbaoui, J.; Protais, P.; Cassels, B.K. Halogenated boldine derivatives with enhanced monoamine receptor selectivity. J. Nat. Prod., 2000, 63, 480-484.
113. Linnanen, T.; Brisander, M.; Unelius, L.; Sundholm, G.; Hacksell, U.; Johansson, A.M. Derivatives of (R)-1,11-methyleneaporphine: synthesis, structure, and interactions with G-protein coupled receptors. J. Med. Chem., 2000, 43, 1339-1349.
114. Linnanen, T.; Brisander, M.; Mohell, N.; Johansson, A.M. Serotonergic and dopaminergic activities of rigidified (R)-aporphine derivatives. Bioorg. Med. Chem. Lett., 2001, 11, 367-370.
115. Collins, M.A. Mammalian alkaloids. In The Alkaloids; Brossi, A., Ed.; Academic Press: New York, 1983; Vol. 21, pp. 329-358.
116. McNaught, K.St.P.; Carrupt, P.-A.; Altomare, C.; Cellamare, S.; Carotti, A.; Testa, B.; Jenner, P.; Marsden, C.D. Isoquinoline derivatives as endogenous neurotoxins in the aetiology of Parkinson's disease. Biochem. Pharmacol., 1998, 56, 921-933.
117. Kawai, H.; Kotake, Y.; Ohta, S. Dopamine transporter and catechol-O-methyltransferase activities are required for the toxicity of 1-(3′,4_p,-dihydroxy-benzyl)-1,2,3,4-tetrahydroisoquinoline. Chem. Res. Toxicol., 2000, 13, 1294-1301.
118. Zenk, M.H.; Rueffer, M.; Amann, M.; Deus-Neumann, B.; Nagakura, N. Benzylisoquinoline biosynthesis by cultivated plant cells and isolated enzymes. J. Nat. Prod., 1985, 48, 725-738.
119. Liscombe, D.K.; Facchini, P.J. Evolutionary and cellular webs in benzylisoquinoline alkaloid biosynthesis. Curr. Opin. Biotechnol., 2008, 19, 173-180.
120. Liscombe, D.K.; MacLeod, B.P.; Loukanina, N., Nandi, O.I.; Facchini, P.J. Evidence for the monophyletic evolution of benzylisoquinoline alkaloid biosynthesis in angiosperms. Phytochemistry, 2005, 66, 1374-1393.
121. Facchini, P.J. Alkaloid biosynthesis in plants: Biochemistry, cell biology, molecular regulation, and metabolic engineering applications. Annu. Rev. Plant Physiol. Plant Mol. Biol., 2001, 52, 29-66.
122. Facchini, P.J.; Hagel, J.M.; Liscombe, D.K.; Loukanina, N.; MacLeod, B.P.; Samanani, N.; Zulak, K.G. Opium poppy: Blueprint for an alkaloid factory. Phytochem. Rev., 2007, 6, 97-124.
123. Maruyama, W.; Sango, K.; Iwasa, K.; Minami, C.; Dostert, P.; Kawai, M.; Moriyasu, M.; Naoi, M. Dopaminergic neurotoxins, 6,7-dihydroxy-1-(3′,4′-dihydroxybenzyl)-isoquinolines, cause different types of cell death in SH-SY5Y cells: Apoptosis was induced by oxidized papaverolines and necrosis by reduced tetrahydropapaverolines. Neurosci. Lett., 2000, 291, 89-92.
124. Brossi, A.; Rice, K.C.; Mak, C.-P.; Reden, J.; Jacobson, A.E.; Nimitkitpaisan, Y.; Skolnick, P.; Daly, J. Mammalian Alkaloids.8. Synthesis and biological effects of tetrahydropapaveroline related 1-benzyltetrahydroisoquinolines. J. Med. Chem., 1980, 23, 648-652.
125. Nimit, Y.; Schulze, I.; Cashaw, J.L.; Ruchirawat, S.; Davis, V.E. Interaction of catecholamine-derived alkaloids with central neurotransmitter receptors. J. Neurosci. Res., 1983, 10, 175-189.
126. Okada, T.; Shimada, S.; Sato, K.; Kotake, Y.; Kawai, H.; Ohta, S.; Tohyama, M.; Nishimura, T.; Tetrahydropapaveroline and its derivatives inhibit dopamine uptake through dopamine transporter expressed in HEK293 cells. Neurosci. Res., 1998, 30, 87-90.
127. 4 Dopamine receptor-selective compounds from the Chinese plant Phoebe chekiangensis. Bioorg. Med. Chem. Lett., 1997, 7, 1207-1212.
128. Bermejo, A.; Protais, P.; Blázquez, M.A.; Rao, K.S.; Zafra-Polo, M.C.; Cortes, D. Dopaminergic isoquinoline alkaloids from roots of Xylopia papuana. Nat. Prod. Lett., 1995, 6, 57-62.
129. Watanabe, H.; Ikeda, M.; Watanabe, K.; Kikuchi, T. Effects on central dopaminergic systems of d-coclaurine and d-reticuline, extracted from Magnolia salicifolia. Planta Med., 1981, 42, 213-222.
130. Morais, L.C.S.L.; Barbosa-Filho, J.M.; Almeida, R.N. Central depressant effects of reticuline extracted from Ocotea duckei in rats and mice. J. Ethnopharmacol., 1998, 62, 57-61.
131. Cabedo, N.; Protais, P.; Cassels, B.K.; Cortes, D. Synthesis and dopamine receptor selectivity of the benzyltetrahydroisoquinoline, (R)-(+)-nor-roefractine. J. Nat. Prod., 1998, 61, 709-712.
132. Kawai, H.; Kotake, Y.; Ohta, S. Inhibition of dopamine receptors by endogenous amines: Binding to striatal receptors and pharmacological effects on locomotor activity. Bioorg. Med. Chem. Lett., 2000, 10, 1669-1671.
133. Cabedo, N.; Andreu, I.; Ramírez de Arellano, M.C.; Chagraoui, A.; Serrano, A.; Bermejo, A.; Protais, P.; Cortes, D. Enantioselective syntheses of dopaminergic (R)- and (S)-benzyltetrahydroisoquinolines. J. Med. Chem., 2001, 44, 1794-1801.
134. 3H-raclopride binding sites. Experientia, 1992, 48, 27-30.
135. Andreu, I.; Cabedo, N.; Torres, G.; Chagraoui, A.; Ramírez de Arellano, M.C.; Gil, S.; Bermejo, A.; Valpuesta, M.; Protais, P.; Cortes, D. Syntheses of dopaminergic 1-cyclohexylmethyl-7,8-dioxygenated tetrahydroisoquinolines by selective heterogeneous tandem hydrogenation. Tetrahedron, 2002, 58, 10173-10179.
136. Charifson, P.S.; Wyrick, S.D.; Hoffman, A.J.; Simmons, R.M.A.; Bowen, J.P.; McDougald, D.L.; Mailman, R.B. Synthesis and pharmacological characterization of 1-phenyl-, 4-phenyl-, and 1-benzyl-1,2,3,4-tetrahydroisoquinolines as dopamine receptor ligands. J. Med. Chem., 1988, 31, 1941-1946.
137. 1 dopamine antagonists. J. Med. Chem., 1994, 37, 4317-4328.
138. 1 dopamine receptor ligands. J. Med. Chem., 1989, 32, 2050-2058.
139. 1H NMR conformational studies and rotational barriers. J. Chil. Chem. Soc., 2004, 49, 17-23.
140. 1 dopamine receptor. A computational approach. J. Mol. Struc. (Theochem), 2003, 666-667, 455-467.
141. Suvire, F.D.; Andreu, I.; Bermejo, A.; Zamora, M.A.; Cortes, D.; Enriz, R.D. Conformational study of N-alkyl-benzyltetrahydroisoquinolines alkaloid. J. Mol. Struc. (Theochem) 2003, 666-667, 109-116.
142. Sugimoto, Y.; Sugimura, Y.; Yamada, Y. Biosynthesis of bisbenzylisoquinoline alkaloids in cultured roots of Stephania cepharantha. FEBS lett., 1990, 273, 82-86.
143. 3-Hraclopride binding sites. J. Nat. Prod., 1992, 55, 1281-1286.
144. 3Hraclopride binding sites. Nat. Prod. Lett., 1993, 3, 233-238.
145. 2 receptors in calf striatum. Zhongguo Yao Li Xue Bao, 1997, 18, 225-230.
146. 2 receptors in calf striatum. Zhongguo Yao Li Xue Bao, 1997, 18, 143-146.
147. Dong, Z.-J.; Guo, X.; Chen, L.-J.; Han, Y.-F.; Jin, G.-Z. Dual actions of (-)-Stepholidine on the dopamine receptor-mediated adenylate cyclase activity in rat corpus striatum. Life Sci., 1997, 61, 465-472.
148. Xu, S.X.; Yu, L.P.; Han, Y.R.; Chen, Y.; Jin, G.Z. Effects of tetrahydroprotoberberines on dopamine receptor subtypes in brain. Zhongguo Yao Li Xue Bao, 1989, 10, 104-110.
149. Tang, Y.; Chen, K.X.; Jiang, H.L.; Jin, G.Z.; Ji, R.Y. Molecular modeling of interactions between tetrahydroprotoberberines and dopamine receptors. Zhongguo Yao Li Xue Bao, 1996, 17, 8-12.
150. 2 receptors in striatum. Zhongguo Yao Li Xue Bao, 1996, 17, 485-489.
151. Guo, X.; Liu, J.; Zou, L.L.; Jin, J.; Wang, B.C.; Jin, G.Z. Enhancement of (-)-stepholidine on protein phosphorylation of a dopamine- and cAMP-regulated phosphoprotein in denervated striatum of oxidopamine-lesioned rats. Zhongguo Yao Li Xue Bao, 1998, 19, 100-103.
152. Ellenbroek, B.A.; Zhang, X.-X.; Jin, G.-Z. Effects of (-)-stepholidine in animal models for schizophrenia. Acta Pharmacologica Sinica, 2006, 27, 1111-1118.
153. 1 dopamine signaling pathway in rat prelimbic cortical neurons. Acta Pharmacologica Sinica, 2007, 28, 627-633.
154. Jiao, M.; Yang, G.; Yu-She, Y.; Jing-Shan, S.; Guo-Zhang, J.; Xuechu, Z. Recent developments in studies of l-stepholidine and its analogs: chemistry, pharmacology and clinical implications. Curr. Med. Chem., 2007, 14, 2996-3002.
155. Chu, H.; Jin, G.; Friedman, E.; Zhen, X. Recent development in studies of tetrahydroprotoberberines: Mechanism in antinociception and drug addiction. Cell Mol. Neurobiol., 2008, 28, 491-499.
156. Cingolani, G.M.; Di Stefano, A.; Napolitani, F.; Mosciatti, B.; Giorgioni, G.; Cinone, N.; Brunetti, L.; Luisi, G.; Michelotto, B.; Orlando, G.; Costa, B.; Lucacchini, A.; Martini, C.; Claudi, F. Synthesis and preliminary pharmacological evaluation of 5-hydroxyand 5,6-dihydroxy-1,2,3,7,12,12a-hexahydrobenzo [5,6]cyclohepta 1,2,3-ij]isoquinoline derivatives as dopamine receptor ligands. Bioorg. Med. Chem., 2001, 9, 1447-1458.
157. 2 dopamine receptors. J. Med. Chem., 1998, 41, 4385-4399.
158. 5 selective antagonist. J. Med. Chem., 2006, 49, 760-769.
159. 2A receptor profile and 3D-QSAR analysis. BMC Pharmacol., 2006, 6, 11-26.
160. 5-selective dopamine-receptor antagonist. J. Med. Chem., 2006, 49, 2110-2116.
161. Wittig, T.W.; Enzensperger, C.; Lehmann, J. Dopamine/serotonin receptor ligands VI. Dibenz[g,j]-1-oxa-4-azacycloundecene and dibenz [d,g]-2-azacycloundecene: Synthesis of two new heterocyclic ring systems as potential ligands for dopamine receptor subtypes. Heterocycles, 2003, 60, 887-898.
162. 5 receptors. J. Med. Chem., 2006, 49, 6408-6411.
163. 5 receptors. J. Med. Chem., 2007, 50, 4528-4533.
164. 1 dopamine agonist dihydroxy-2,3,7,11b-tetrahydro-1H-naphth[1,2,3-de] isoquinoline: Dinapsoline. J. Org. Chem., 1999, 64, 1407-1409.
165. 2 dopamine receptor ligands. Bioorg. Med. Chem., 2003, 11, 1451-1464.
166. Sit, S.-Y.; Xie, K.; Jacutin-Porte, S.; Taber, M.T.; Gulwadi, A.G.; Korpinen, C.D.; Burris, K.D.; Molski, T.F.; Ryan, E.; Xu, C.; Wong, H.; Zhu, J.; Krishnananthan, S.; Gao, Q.; Verdoorn, T.; Jonson, G. (+)-Dinapsoline: An efficient synthesis and pharmacological profile of a novel dopamine agonist. J. Med. Chem., 2002, 45, 3660-3668.
167. 1 receptor agonist. Eur. J. Pharmacol., 1989, 166, 111-113.
168. 1 dopamine receptor agonist. J. Med. Chem., 1994, 37, 2453-2460.
169. 1 dopamine receptor ligands. J. Med. Chem., 1995, 38, 318-327.
170. 2 dopamine receptors. J. Med. Chem., 1995, 38, 3062-3070.
171. Carroll, F.I.; Lewin, A.H.; Boja, J.W.; Kuhar, M.J. Cocaine receptor: biochemical and characterization and structure-activity relationships of cocaine analogs at the dopamine transporter. J. Med. Chem., 1992, 35, 969-981.
172. Carroll, F.I.; Howell, L.L.; Kuhar, M.J. Pharmacotherapies for treatment of cocaine abuse: Preclinical aspects. J. Med. Chem., 1999, 42, 2721-2736.
173. Newman, A.H.; Allen, A.C.; Izenwasser, S.; Katz, J.L. Novel 3α-(diphenylmethoxy)tropane analogs: Potent dopamine uptake inhibitors without cocaine-like behavioral profiles. J. Med. Chem., 1994, 37, 2258-2261.
174. Matecka, D.; Rothman, R.B.; Radesca, L.; de Costa, B.R.; Dersch, C.M.; Partilla, J.S.; Pert, A.; Glowa, J.R.; Wojnicki, F.H.E.; Rice, K.C. Development of novel, potent, and selective dopamine reuptake inhibitors through alteration of the piperazine ring of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[bis(4-fluorophenyl) methoxy] ethyl]-4-(3-phenylpropyl)piperazines (GBR12935 and GBR12909). J. Med. Chem., 1996, 39, 4704-4716.
175. Kozikowski, A.P.; Araldi, G.L.; Boja, J.; Meil, W.M.; Johnson, K.M.; Flippen-Anderson, J.L.; George, C.; Saiah, E. Chemistry and pharmacology of the piperidine-based analogues of cocaine. Identification of potent DAT inhibitors lacking the tropane skeleton. J. Med. Chem., 1998, 41, 1962-1969.
176. Tamiz, A.P.; Zhang, J.; Flippen-Anderson, J.L.; Zhang, M.; Johnson, K.M.; Deschaux, O.; Tella, S.; Kozikowski, A.P. Further SAR studies of piperidine-based analogues of cocaine. 2. Potent dopamine and serotonin reuptake inhibitors. J. Med. Chem., 2000, 43, 1215-1222.
177. 3H-dopamine uptake by rat striatal synaptosomes. J. Nat. Prod., 1995, 58, 1475-1484.
178. Larson, R. A. The antioxidants of higher-plants. Phytochemistry, 1988, 27, 969-978.
179. Matsuno, T.; Orita, K.; Edashige, K.; Kobuchi, H.; Sato, E.F.; Inouye, B.; Inoue, M.; Utsumi, K. Inhibition of active oxygen generation in Guinea-pig neutrophils by biscoclaurine alkaloids. Biochem. Pharmacol., 1990, 39, 1255-1259.
180. Ju, H.S.; Li, X.J.; Zhao, B.L.; Han, Z.W.; Xin, W. J. Scavenging effect of berbamine on active oxygen radicals in phorbol ester-stimulated human polymorphonuclear leukocytes. Biochem. Pharmacol., 1990, 39, 1673-1678.
181. Martinez, L.A.; Ríos, J.L.; Paya, M.; Alcaraz, M.J. Inhibition of nonenzymic lipid-peroxidation by benzylisoquinoline alkaloids. Free Radic. Biol. Med., 1992, 12, 287-292.
182. Speisky, H.; Cassels, B.K. Boldo and boldine: An emerging case of natural drug development. Pharmacol. Res., 1994, 29, 1-12.
183. Cassels, B.K.; Asencio, M.; Conget, P.; Speisky, H.; Videla, L.A.; Lissi, E.A. Structure-antioxidative activity relationships in benzylisoquinoline alkaloids. Pharmacol. Res., 1995, 31, 103-107.
184. Speisky, H.; Cassels, B.K.; Lissi, E.A.; Videla, L.A. Antioxidant properties of the alkaloid boldine in systems undergoing lipid-peroxidation and enzyme inactivation. Biochem. Pharmacol., 1991, 41, 1575-1581.
185. Bannach, R.; Valenzuela, A.; Cassels, B.K.; Núñez-Vergara, L.J.; Speisky, H. Cytoprotective and antioxidant effects of boldine on tert-butyl hydroperoxide-induced damage to isolated hepatocytes. Cell Biol. Toxicol., 1996, 12, 89-100.
186. Jiménez, I.; Garrido, A.; Bannach, R.; Gotteland, M.; Speisky, H. Protective effects of boldine against free radical-induced erythrocyte lysis. Phytother. Res., 2000, 14, 339-343.
187. Loghin, F.; Chagraoui, A.; Asencio, M.; Comoy, E.; Speisky, H.; Cassels, B.K.; Protais, P. Effects of some antioxidative aporphine derivatives on striatal dopaminergic neurotransmission and on MPTP-induced striatal dopamine depletion in B6CBA mice. Eur. J. Pharm. Sci., 2003, 18, 133-140.
188. O'Brien, P.; Carrasco-Pozo, C.; Speisky, H. Boldine and its antioxidant or health-promoting properties. Chem.-Biol. Interact., 2006, 159, 1-17.
189. 7 receptor antagonists. Curr. Med. Chem., 2004, 4, 203-214.
190. 7 receptors. J. Comput.-Aided Mol. Des., 2001, 15, 883-909.
191. 7 receptor agonism and CoMFA-based modeling of the agonist binding site. J. Med. Chem., 2003, 46, 5365-5374.
192. Cannon, J.G.; Mohan, P.; Bojarski, J.; Long, J.P.; Bhatnagar, R.K.; Leonard, P.A.; Flynn, J.R.; Chatterjee, T.K. (R)-(-)-10-Methyl-11-hydroxyaporphine: A highly selective serotonergic agonists. J. Med. Chem., 1988, 31, 313-318.
193. 1A receptor interactions. J. Med. Chem., 1996, 39, 3491-3502.
194. Indra, B.; Tadano, T.; Nakagawasai, O.; Arai, Y.; Yasuhara, H.; Ohizumi, Y.; Kisara, K. Suppressive effect of nantenine, isolated from Nandina domestica Thunberg on the 5-hydroxy-L-tryptophan plus clorgyline-induced head-twitch response in mice. Life Sci., 2002, 70, 2647-2656.
195. Cannon, J.G.; Raghupathi, R.; Moe, S.T.; Johnson, A.K.; Long, J.P. Preparation and pharmacological evaluation of enantiomers of certain nonoxygenated aporphines: (+)- and (-)-aporphine and (+)-and (-)-10-methylaporphine. J. Med. Chem., 1993, 36, 1316-1318.
196. 1A receptors. J. Med. Chem., 1995, 38, 1841-1845.
197. 7 receptor antagonists. J. Med. Chem., 2001, 44, 1337-1340.
198. Hasrat, J.A.; De Bruyne, T.; De Backer, J.P.; Vauquelin, G.; Vlietinck, A.J. Isoquinoline derivatives isolated from the fruit of Annona muricata as 5-HTergic 5-HT1A receptor agonists in rats: Unexploited antidepressive (lead) products. J. Pharm. Pharmacol., 1997, 49, 1145-1149.
199. 1A receptors. Chirality, 1991, 3, 19-23.
200. 1A receptors in vitro. J. Nat. Prod., 2006, 69, 432-435.
201. Catret, M.; Ivorra, M.D.; D'Ocón, M.P.; Anselmi, E. The 5-HT and α-adrenoreceptor antagonist effect of four benzylisoquinoline alkaloids on rat aorta. J. Pharm. Pharmacol., 1998, 50, 317-322.
202. Zhang, Y.-H.; Fang, L.-H. Antagonism of morphine-induced antinociception by tetrandrine is dependent on serotonergic mechanisms. Life Sci., 2001, 69, 1429-1439.
203. Zhao, X.; Cui, X.-Y.; Chen, B.-Q.; Chu, Q.-P.; Yao, H.-Y.; Ku, B.-S.; Zhang, Y.-H. Tetrandrine, a bisbenzylisoquinoline alkaloid from Chinese herb Radix, augmented the hypnotic effect of pentobarbital through serotonergic system. Eur. J. Pharmacol., 2004, 506, 101-105.
204. Fang, L.-H.; Zhang, Y.-H.; Ku, B.-S. Fangchinoline inhibited the antinociceptive effect of morphine in mice. Phytomedicine, 2005, 12, 183-188.
205. Xu, L.-F.; Chu, W.-J.; Qing, X.-Y.; Li, S.; Wang, X.-S.; Qing, G.-W.; Fei, J.; Guo, L.-H. Protopine inhibits serotonin transporter and noradrenaline transporter and has the antidepressant-like effect in mice models. Neuropharmacology, 2006, 50, 934-940.
206. Chrzanowska, M.; Rozwadowska, M.D. Asymmetric synthesis of isoquinoline alkaloids. Chem. Rev., 2004, 104, 3341-3370.
207. Lafrance, M.; Blaquière, N.; Fagnou, K. Direct intramolecular arylation of unactivated arenes: Application to the synthesis of aporphine alkaloids. Chem. Commun., 2004, 2874-2875.
208. Lafrance, M.; Blaquière, N.; Fagnou, K. Aporphine alkaloid synthesis and diversification via direct arylation. Eur. J. Org. Chem., 2007, 811-825.
209. Rodrigues, J.A.R.; Abramovitch, R.A.; de Sousa, J.D.F.; Leiva, G.C. Diastereoselective synthesis of cularine alkaloids via enium ions and an easy entry to isoquinolines by aza-Wittig electrocyclic ring closure. J. Org. Chem., 2004, 69, 2920-2928.
210. Liu, Z.; Chen, X.; Yu, L.; Zhen, X.; Zhang, A. Synthesis and pharmacological investigation of novel 2-aminothiazole-privileged aporphines. Bioorg. Med. Chem., 2008, 16, 6675-6681.
211. Liu, Z.; Chen, X.; Sun, P.; Yu, L.; Zhen, X.; Zhang, A. Bioorg. Med. Chem., 2008, 16, 8335-8338.
212. Rasmussen, S.G.F.; Choi, H.J.; Rosenbaum, D.M.; Kobilka, T.S.; Thian, F.S.; Edwards, P.C.; Burghammer, M.; Ratnala, V.R.P.; Sanishvili, R.; Fischetti, R.F.; Schertler, G.F.X.; Weis, W.I.; Kobilka, B.K. Nature, 2007, 450, 383-388.
213. Cherezov, V.; Rosenbaum, D.M.; Hanson, M.A.; Rasmussen, S.G.F.; Thian, F.S.; Kobilka, T.S.; Choi, H.J.; Kuhn, P.; Weis, W.I.; Kobilka, B.K.; Stevens, R.C. Science, 2007, 318, 1258-1265.
214. Rosenbaum, D.M.; Cherezov, V.; Hanson, M.A.; Rasmussen, S.G.F.; Thian, F.S.; Kobilka, T.S.; Choi, H.J.; Yao, X.-J.; Weis, W.I.; Stevens, R.C.; Kobilka, B.K. Science, 2007, 318, 1266-1273.
215. 1-adrenergic G-protein-coupled receptor. Nature, 2008, 454, 486-491.
216. Shukla, A.K.; Sun, J.-P.; Lefkowitz, R.J. Crystallizing thinking about the β2-adrenergic receptor. Mol. Pharmacol., 2008, 73, 1333-1338.
217. 2-adrenergic receptor and its interaction with Salmeterol & Nifedipine. J. Mol. Model, 2008, 14, 849-856.